Bioenvision Appoints James S. Scibetta as New CFO

  
    
  
  
    
      Bioenvision, Inc. (NasdaqGM:BIVN) today announced the appointment James 
      S. Scibetta to the post of Chief Financial Officer. Mr. Scibetta will 
      begin his employment with Bioenvision in early December 2006.
    
    
      Mr. Scibetta, with 18 years of experience as a finance professional, 
      will become the Company’s new CFO. Mr. 
      Scibetta was most recently Executive Vice President & CFO of Merrimack 
      Pharmaceuticals, Inc. of Cambridge, Massachusetts, a biopharmaceutical 
      company focused on discovery and development of novel therapies for 
      autoimmune disease and cancer. Mr. Scibetta is a member of the board of 
      directors and audit committee chairman of Labopharm Inc. (Nasdaq:DDSS, 
      TSX:DDS), an international, specialty pharmaceutical company focused on 
      improving existing drugs by incorporating its proprietary, advanced 
      controlled-release technologies, and formerly has served as a senior 
      investment banker providing capital raising, M&A and strategic advisory 
      services to healthcare companies at Shattuck Hammond Partners, LLC, a 
      boutique healthcare investment bank and PaineWebber Inc.
    
    
      “We are very pleased to have someone with Jim’s 
      experience joining the Bioenvision team,” 
      said Dr. Christopher Wood, Bioenvision’s 
      Chairman and CEO.
    
    
      Mr. Scibetta said. “I look forward to working 
      with the current management team and using my skills and experience to 
      help Bioenvision manage through the coming stages of growth and 
      opportunity.”
    
    
      David P. Luci, formerly Bioenvision’s Chief 
      Financial Officer, General Counsel and Corporate Secretary, will be 
      promoted to the position of Executive Vice President, General Counsel 
      and Corporate Secretary, focusing on business and product development 
      activities and continuing to manage the Company’s 
      legal and regulatory matters.
    
    
      About Bioenvision
    
    
      Bioenvision’s primary focus is the 
      acquisition, development, distribution and marketing of compounds and 
      technologies for the treatment of cancer. Bioenvision has a broad 
      pipeline of products for the treatment of cancer, including: Evoltra®, 
      Modrenal® (for which 
      Bioenvision has obtained regulatory approval for marketing in the United 
      Kingdom for the treatment of post-menopausal breast cancer following 
      relapse to initial hormone therapy), and other products. Bioenvision is 
      also developing anti-infective technologies, including the OLIGON® 
      technology, an advanced biomaterial that has been incorporated into 
      various FDA approved medical devices and Suvus®, 
      an antimicrobial agent currently in clinical development for refractory 
      chronic hepatitis C infection. For more information on Bioenvision 
      please visit our Web site at www.bioenvision.com.
    
    
      Certain statements contained herein are “forward-looking” 
      statements (as such term is defined in the Private Securities Litigation 
      Reform Act of 1995). Because these statements include risks and 
      uncertainties, actual results may differ materially from those expressed 
      or implied by such forward-looking statements. Specifically, factors 
      that could cause actual results to differ materially from those 
      expressed or implied by such forward-looking statements include, but are 
      not limited to: risks associated with preclinical and clinical 
      developments in the biopharmaceutical industry in general and in 
      Bioenvision's compounds under development in particular; the potential 
      failure of Bioenvision's compounds under development to prove safe and 
      effective for treatment of disease; uncertainties inherent in the early 
      stage of Bioenvision's compounds under development; failure to 
      successfully implement or complete clinical trials; failure to receive 
      marketing clearance from regulatory agencies for our compounds under 
      development; acquisitions, divestitures, mergers, licenses or strategic 
      initiatives that change Bioenvision's business, structure or 
      projections; the development of competing products; uncertainties 
      related to Bioenvision's dependence on third parties and partners; and 
      those risks described in Bioenvision's filings with the SEC. Bioenvision 
      disclaims any obligation to update these forward-looking statements.
    
  
Bioenvision, Inc. (NasdaqGM:BIVN) today announced the appointment
James S. Scibetta to the post of Chief Financial Officer. Mr. Scibetta
will begin his employment with Bioenvision in early December 2006.

   Mr. Scibetta, with 18 years of experience as a finance
professional, will become the Company's new CFO. Mr. Scibetta was most
recently Executive Vice President & CFO of Merrimack Pharmaceuticals,
Inc. of Cambridge, Massachusetts, a biopharmaceutical company focused
on discovery and development of novel therapies for autoimmune disease
and cancer. Mr. Scibetta is a member of the board of directors and
audit committee chairman of Labopharm Inc. (Nasdaq:DDSS, TSX:DDS), an
international, specialty pharmaceutical company focused on improving
existing drugs by incorporating its proprietary, advanced
controlled-release technologies, and formerly has served as a senior
investment banker providing capital raising, M&A and strategic
advisory services to healthcare companies at Shattuck Hammond
Partners, LLC, a boutique healthcare investment bank and PaineWebber
Inc.

   "We are very pleased to have someone with Jim's experience joining
the Bioenvision team," said Dr. Christopher Wood, Bioenvision's
Chairman and CEO.

   Mr. Scibetta said. "I look forward to working with the current
management team and using my skills and experience to help Bioenvision
manage through the coming stages of growth and opportunity."

   David P. Luci, formerly Bioenvision's Chief Financial Officer,
General Counsel and Corporate Secretary, will be promoted to the
position of Executive Vice President, General Counsel and Corporate
Secretary, focusing on business and product development activities and
continuing to manage the Company's legal and regulatory matters.

   About Bioenvision

   Bioenvision's primary focus is the acquisition, development,
distribution and marketing of compounds and technologies for the
treatment of cancer. Bioenvision has a broad pipeline of products for
the treatment of cancer, including: Evoltra(R), Modrenal(R) (for which
Bioenvision has obtained regulatory approval for marketing in the
United Kingdom for the treatment of post-menopausal breast cancer
following relapse to initial hormone therapy), and other products.
Bioenvision is also developing anti-infective technologies, including
the OLIGON(R) technology, an advanced biomaterial that has been
incorporated into various FDA approved medical devices and Suvus(R),
an antimicrobial agent currently in clinical development for
refractory chronic hepatitis C infection. For more information on
Bioenvision please visit our Web site at www.bioenvision.com.

   Certain statements contained herein are "forward-looking"
statements (as such term is defined in the Private Securities
Litigation Reform Act of 1995). Because these statements include risks
and uncertainties, actual results may differ materially from those
expressed or implied by such forward-looking statements. Specifically,
factors that could cause actual results to differ materially from
those expressed or implied by such forward-looking statements include,
but are not limited to: risks associated with preclinical and clinical
developments in the biopharmaceutical industry in general and in
Bioenvision's compounds under development in particular; the potential
failure of Bioenvision's compounds under development to prove safe and
effective for treatment of disease; uncertainties inherent in the
early stage of Bioenvision's compounds under development; failure to
successfully implement or complete clinical trials; failure to receive
marketing clearance from regulatory agencies for our compounds under
development; acquisitions, divestitures, mergers, licenses or
strategic initiatives that change Bioenvision's business, structure or
projections; the development of competing products; uncertainties
related to Bioenvision's dependence on third parties and partners; and
those risks described in Bioenvision's filings with the SEC.
Bioenvision disclaims any obligation to update these forward-looking
statements.